Ipsen (0MH6) Stock Overview

A biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. More details

0MH6 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	1/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 41.2% below our estimate of its fair value

Earnings are forecast to grow 11.3% per year

Risk Analysis

Large one-off items impacting financial results

0MH6 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Ipsen S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Ipsen
Historical stock prices
Current Share Price	€157.20
52 Week High	€176.60
52 Week Low	€100.40
Beta	0.32
1 Month Change	-4.61%
3 Month Change	2.21%
1 Year Change	51.01%
3 Year Change	42.16%
5 Year Change	73.94%
Change since IPO	319.42%

Recent updates

Shareholder Returns

	0MH6	GB Pharmaceuticals	GB Market
7D	1.6%	1.0%	-0.8%
1Y	51.0%	17.4%	15.5%

Return vs Industry: 0MH6 exceeded the UK Pharmaceuticals industry which returned 17.7% over the past year.

Return vs Market: 0MH6 exceeded the UK Market which returned 15.2% over the past year.

Price Volatility

Is 0MH6's price volatile compared to industry and market?
0MH6 volatility
0MH6 Average Weekly Movement	4.2%
Pharmaceuticals Industry Average Movement	5.7%
Market Average Movement	5.6%
10% most volatile stocks in GB Market	11.7%
10% least volatile stocks in GB Market	3.1%

Stable Share Price: 0MH6 has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0MH6's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1929	5,535	David Loew	www.ipsen.com

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. Its oncology products include Somatuline for the treatment of neuroendocrine tumors; Cabometyx, a tyrosine kinase inhibitor to treat advanced tumor that affecting kidney; Onivyde, an irinotecan liposome injection for the treatment of metastatic pancreatic adenocarcinoma; Somatuline Autogel for the treatment of neuroendocrine tumors; and Ojemda, a Type II RAF kinase inhibitor of BRAF that is in phase III clinical trial for the treatment of pediatric low-grade glioma tumor. It also develops IPN01195, IPN60300, and IPN01203, which are in phase I clinical trial for the treatment of solid tumors; and IPN60340, BTN3A T cell activator that is in Phase II clinical trial for the treatment of acute myeloid leukemia.

Ipsen S.A. Fundamentals Summary

How do Ipsen's earnings and revenue compare to its market cap?
0MH6 fundamental statistics
Market cap	€12.90b
Earnings (TTM)	€443.50m
Revenue (TTM)	€3.93b

29.1x

P/E Ratio

3.3x

P/S Ratio

Is 0MH6 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0MH6 income statement (TTM)
Revenue	€3.93b
Cost of Revenue	€750.90m
Gross Profit	€3.18b
Other Expenses	€2.73b
Earnings	€443.50m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

Jul 30, 2026

Earnings per share (EPS)	5.40
Gross Margin	80.89%
Net Profit Margin	11.29%
Debt/Equity Ratio	19.7%

How did 0MH6 perform over the long term?

See historical performance and comparison

Dividends

0.9%

Current Dividend Yield

26%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/11 13:47
End of Day Share Price	2026/06/11 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ipsen S.A. is covered by 26 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Richard Silver	Barclays
Charles Pitman	Barclays
Yihan Li	Barclays

Ipsen (0MH6) Stock Overview

Rewards

Risk Analysis

Ipsen S.A. Competitors

Haleon

Hikma Pharmaceuticals

GSK

HUTCHMED (China)

Price History & Performance

Recent News & Updates

Ipsen Presents New Late-Breaking Results and Real-World Evidence for IQIRVO in Primary Biliary Cholangitis

Upcoming dividend of €1.60 per share

Ipsen Announces Late-Breaking Data from First Head-To-Head Study Comparing Dysport and Botox in Adults with Upper Limb Spasticity

Ipsen Presents First-In-Class Phase II Corabotase Data In Glabellar Lines

Ipsen Unveils Corabotase, First-In-Class Recombinant Neuroinhibitor RNI

Ipsen S.A. Confirms Financial Guidance for the Full-Year 2026

Recent updates

Ipsen Presents New Late-Breaking Results and Real-World Evidence for IQIRVO in Primary Biliary Cholangitis

Upcoming dividend of €1.60 per share

Ipsen Announces Late-Breaking Data from First Head-To-Head Study Comparing Dysport and Botox in Adults with Upper Limb Spasticity

Ipsen Presents First-In-Class Phase II Corabotase Data In Glabellar Lines

Ipsen Unveils Corabotase, First-In-Class Recombinant Neuroinhibitor RNI

Ipsen S.A. Confirms Financial Guidance for the Full-Year 2026

Ipsen Receives European Union Approval for Ojemda as Targeted Therapy in Relapsed or Refractory Pediatric Low-Grade Glioma

Dividend increased to €1.60

Ipsen S.A., Annual General Meeting, May 13, 2026

Ipsen Showcases Transformative Potential of Early Immuno-Oncology Pipeline At AACR

Ipsen Announces Executive Changes

Ipsen Voluntarily Withdraws Tazverik in Follicular Lymphoma and Epithelioid Sarcoma

Ipsen S.A. to Report First Half, 2026 Results on Jul 30, 2026

Full year 2025 earnings released: EPS: €5.37 (vs €4.30 in FY 2024)

New major risk - Revenue and earnings growth

Ipsen S.A. Provides Earnings Guidance for the Full Year 2026

Ipsen Nominates Peter Guenter to its Board of Directors, Effective January 28, 2026

Ipsen Announces Executive Changes

Now 20% undervalued

Ipsen Announces the Presentation of 14 Across Multiple Neurological Conditions At the Toxins 2026 Conference in Madrid, Spain

Ipsen Announces Pivotal Phase II FALKON Trial Do Not Meet Its Primary Endpoint of Reducing New Heterotopic Ossification in Adults and Children Living with Fibrodysplasia Ossificans Progressiva

Ipsen S.A. (ENXTPA:IPN) completed the acquisition of ImCheck Therapeutics SAS from Kurma Partners SA, Gimv NV (ENXTBR:GIMB) and others.

Now 20% undervalued

Ipsen Announces Demise of Board Member Henri Beaufour on November 28, 2025

Now 20% undervalued

Ipsen S.A. to Report Q4, 2025 Results on Feb 12, 2026

Ipsen Announces That Japan's Ministry of Health, Labour and Welfare Grants Regulatory Approval for Bylvay®? (Odevixibat) for the Treatment of Pruritus Associated with Progressive Familial Intrahepatic Cholestasis

Medison and Ipsen Announces Health Canada Approves Bylvay™? (odevixibat) for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

First half 2025 earnings released: EPS: €4.04 (vs €2.92 in 1H 2024)

Ipsen S.A. Revises Earnings Guidance for the Year 2025

Exelixis, Inc. Partner Ipsen Receives European Commission Approval for CABOMETYX®? (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Ipsen S.A. Announces New Appointments to Its Executive Committee

Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Upcoming dividend of €1.40 per share

Ipsen Announces New Data from Two Late-Breaking Presentations on IQIRVO®? (elafibranor) During the European Association for the Study of the Liver Congress

Ipsen to Present Data from the Late-Breaking Elafibranor in the Investigational Phase II ELMWOOD Study at the European Association for the Study of the Liver (EASL) Congress

Dividend increased to €1.40

Ipsen S.A. Confirms Guidance for the Full-Year 2025

Ipsen S.A. Provides Earnings Guidance for the Year 2025

Full year 2024 earnings released: EPS: €4.30 (vs €7.46 in FY 2023)

Ipsen S.A., Annual General Meeting, May 21, 2025

Ipsen S.A. to Report Fiscal Year 2024 Results on Feb 13, 2025

Ipsen Provides Update on CONTACT-02 Phase III Trial in Metastatic Castration-Resistant Prostate Cancer Following Final Overall Survival Analysis

First half 2024 earnings released: EPS: €2.92 (vs €2.36 in 1H 2023)

Ipsen Receives CHMPPositive Opinions for Iqirvo® (Elafibranor) in Primary Biliary Cholangitis and Kayfanda® (Odevixibat) in Alagille Syndrome, Two Rare Cholestatic Liver Diseases

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2024

Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis

Ipsen S.A. Approves Dividend, Payable on 3 June 2024

Upcoming dividend of €1.20 per share

Ipsen Announces Executive Changes

Dividend of €1.20 announced

Ipsen’s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA

Full year 2023 earnings released: EPS: €7.79 (vs €7.20 in FY 2022)

Ipsen Announces Latest Phase III Trial Data Investigating Cabometyx®? in Combination with Immunotherapy to Be Present at ASCO Gu 2024

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

Ipsen S.A. to Report Q4, 2023 Results on Feb 08, 2024

Ipsen S.A. Confirms Sales Guidance for the Fiscal Year 2023

Ipsen S.A., Annual General Meeting, May 28, 2024

IRLAB Therapeutics AB Announces Further Information on Results from Mesdopetam’s Clinical Phase IIb Study in Parkinson’s Disease Levodopa-Induced Dyskinesias and Phase III Preparatory Phase I Studies Performed by Ipsen

First half 2023 earnings released: EPS: €2.36 (vs €4.63 in 1H 2022)

New minor risk - Profit margin trend

Ipsen Provides Update on E.U. Marketing Authorization Application for Bylvay for Cholestatic Pruritus in Patients with Alagille Syndrome